Failure to seroconvert after two doses of BNT162b2 SARS-CoV-2 vaccine in a patient with uncontrolled HIV.

Published version
Repository URI
https://www.repository.cam.ac.uk/handle/1810/327925
Repository DOI
https://doi.org/10.17863/CAM.75378
Files
Published version (113.38 KB)
Type
Article
Change log
Authors
Touizer, Emma 
Alrubayyi, Aljawharah 
Rees-Spear, Chloe 
Fisher-Pearson, Natasha 
Griffith, Sarah A 
Show 5 more
Description
Keywords
Adenine, Adult, Alanine, Amides, Antiretroviral Therapy, Highly Active, BNT162 Vaccine, CD4 Lymphocyte Count, CD4-CD8 Ratio, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, COVID-19, COVID-19 Vaccines, Emtricitabine, HIV Infections, HIV-1, Heterocyclic Compounds, 3-Ring, Heterocyclic Compounds, 4 or More Rings, Humans, Neutralization Tests, Piperazines, Pyridones, RNA, Viral, SARS-CoV-2, Tenofovir, Treatment Failure
Journal Title
Lancet HIV
Conference Name
Journal ISSN
2405-4704
2352-3018
Volume Title
8
Publisher
Elsevier BV
Publisher DOI
https://doi.org/10.1016/S2352-3018(21)00099-0
Rights
Publisher's own licence
Collections
Cambridge University Research Outputs